European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 17 · Tue 6 Oct 

Molecules

Brenipatide

LY3537031

1 asset15 European trial records0 deals

Assets

European trials

Austria 2

Belgium 8

Czechia 2

Denmark 2

France 4

Germany 13

Greece 3

Hungary 2

Netherlands 2

Poland 9

Romania 2

Spain 7

Our calls

  • Issue 12OpenBefore 31 December 2026, at least one additional EU member state will appear across Lilly's five brenipatide CTIS trials, beyond the current five (Belgium, Germany, Greece, Poland, Spain). Our read that a trial engine that added four national approvals in seven days keeps expanding.
  • Issue 11OpenBefore 31 December 2026 the ClinicalTrials.gov record for NCT07775300 (Lilly, brenipatide, Phase 3 MDD) will show overall status RECRUITING AND still carry at least one of Germany, Greece, Poland, Spain or the United Kingdom in its location list. Our read of whether the EU-member site list is real intent or paperwork.

Record history